Helus Pharma, a clinical stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions, announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational strategy, talent development, corporate communications, investor relations, and building commercial teams.
Throughout her career, Conwell has helped biotechnology and pharmaceutical companies design and scale organizations to support evolving business strategies, including periods of rapid growth, pipeline advancement, and corporate transformation. She previously held senior leadership roles at Aclaris Therapeutics, Idera Pharmaceuticals, and Shire Pharmaceuticals, where she was an integral member of executive leadership and partnered closely with boards. In addition to leading human resources functions, she has also worked across corporate communications and investor relations.
Company Development and Focus
Michael Cola, Chief Executive Officer of Helus Pharma, stated: “Jill has a proven ability to help life sciences companies build and align teams, organizational strategies, and processes to support ambitious growth. As Helus Pharma advances our clinical programs and prepares for the next phase of growth, Jill’s experience will be invaluable in helping us attract top talent, advance our culture, and scale the organization to support the business.”
Conwell expressed enthusiasm for joining the company: “I’m excited to join Helus Pharma at such a pivotal time for the company. Helus Pharma is advancing an innovative approach to addressing serious mental health conditions, and I value the opportunity to help the team execute on our scientific and strategic goals while maintaining a strong, collaborative, and mission-driven culture.” Conwell holds an MBA in Strategic Management and Organizational Management from The Wharton School at the University of Pennsylvania and a B.S. in Chemical Engineering from the University of Virginia. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder with Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110851777/Helus-Pharma-Strengthens-Executive-Team-With-Appointment-Of-Jill-Conwell-As-Chief-People-Officer